RSV
呼吸道合胞病毒（RSV）疫苗
A new vaccine category in HK. Two products now registered, targeting older adults and pregnancy. Not yet in the public programme.
Arexvy · Abrysvo
What is it?
Respiratory syncytial virus (RSV) is a common respiratory virus. In older adults (60+) and infants it can cause severe RSV pneumonia, bronchiolitis, and hospitalisation.
Two RSV vaccines are now registered in HK:
- Arexvy (GSK): recombinant protein vaccine for adults 60+
- Abrysvo (Pfizer): recombinant protein vaccine for adults 60+ AND for use in pregnancy (32-36 weeks) to protect newborns through maternal antibodies
Both are available in the private sector. The HK Government has not yet added RSV vaccination to the public programme.
HK Department of Health recommendation
HK Department of Health has not yet issued formal SCVPD recommendations on RSV vaccination as of mid-2026.
People most likely to benefit based on international guidance and HK disease burden:
- Adults aged 75+, especially in residential care homes
- Adults 60-74 with chronic conditions (heart disease, COPD, diabetes, kidney disease, immunocompromise)
- Pregnant women between 32-36 weeks (specifically Abrysvo) — to protect newborns
If you fall into one of these groups, discuss with your GP. Private cost in HK: roughly HK$1,500-2,500 per dose.
International reference (US CDC)
US CDC recommends RSV vaccine for adults 75+ (single dose), adults 60-74 with risk conditions, and pregnant women at 32-36 weeks (Abrysvo) as one option for protecting newborns.
Schedule
Older adults: single dose. Whether revaccination is needed is still being studied.
Pregnant women (Abrysvo): single dose between 32-36 weeks of pregnancy.
HK-registered products
| Brand | Manufacturer | HK Reg No. |
|---|---|---|
| Arexvy · Recombinant RSV prefusion F protein + AS01E adjuvant | GSK | HK-67997 |
| Abrysvo · Bivalent recombinant RSV prefusion F protein | Pfizer | HK-68213 |
Side effects
Sore arm, swelling, tiredness, mild headache, muscle aches, mild fever.
A small signal of Guillain-Barré syndrome has been reported — roughly 1-3 extra cases per million doses. Regulators consider benefits to outweigh this risk for the recommended age groups.
Common myths
Myth: RSV is a baby illness — adults don't need a vaccine for it.
Reality: RSV causes tens of thousands of adult hospitalisations annually. Older adults bear most of the burden.
Myth: It's a brand new vaccine — too risky.
Reality: The vaccines are recently approved, but the science is mature. Phase 3 trials covered tens of thousands of people and real-world surveillance is adding data.
Where to get it
- Older adults: see your GP. Both Arexvy and Abrysvo available in the private sector.
- Pregnant women: see your obstetrician or GP for Abrysvo at 32-36 weeks. Private cost applies.
Packages & prices
Checked weekly against each provider's own published prices.
- Quality HealthCare Medical CentreClinicLast verified 10 Jul 2026Source ↗HK$2,563Book on clinic site ↗
Prices and terms change often and many are limited-time promotions — confirm the current price and availability with the provider before booking. hkvaccines.com is independent: we take no payment for bookings or placement.
Sources
- HK Drug Office — Abrysvo (Pfizer) registration HK-68213 · HK Drug Office (HK)
- HK Drug Office — Arexvy (GSK) registration HK-67997 · HK Drug Office (HK)
Related vaccines
Related questions
The recommender
Answer six short questions to see which vaccines are worth discussing with your GP, and why.
Based on your age, health, and travel plans, using HK Department of Health and CDC guidance. A ranked list of vaccines, with the reason each one applies to you.
Rule-based
The recommendations follow HK Department of Health and US CDC guidance, and you can see how each one was reached.
Private
Your answers stay on your own device. We never receive or store them.
Explained
Every recommendation comes with the reason it applies to you.